Boston Trust Walden Corp Has $51.25 Million Stock Holdings in Globus Medical, Inc. (NYSE:GMED)

Boston Trust Walden Corp reduced its position in shares of Globus Medical, Inc. (NYSE:GMED) by 15.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 619,652 shares of the medical device company’s stock after selling 110,272 shares during the period. Boston Trust Walden Corp owned approximately 0.46% of Globus Medical worth $51,251,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GMED. Oak Thistle LLC acquired a new position in shares of Globus Medical during the 4th quarter worth $376,000. Kathmere Capital Management LLC bought a new position in Globus Medical in the fourth quarter valued at about $23,091,000. Sanctuary Advisors LLC acquired a new position in Globus Medical during the second quarter worth about $611,000. Quest Partners LLC bought a new position in shares of Globus Medical in the third quarter worth about $523,000. Finally, Intech Investment Management LLC boosted its stake in shares of Globus Medical by 291.3% in the 3rd quarter. Intech Investment Management LLC now owns 20,530 shares of the medical device company’s stock valued at $1,469,000 after purchasing an additional 15,283 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on GMED shares. BTIG Research increased their price objective on shares of Globus Medical from $87.00 to $91.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. Piper Sandler increased their price target on Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Stifel Nicolaus boosted their price objective on Globus Medical from $80.00 to $92.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Bank of America raised Globus Medical from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $80.00 to $97.00 in a report on Thursday, January 9th. Finally, Roth Mkm lifted their price target on Globus Medical from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and an average price target of $96.91.

Globus Medical Price Performance

Shares of GMED stock opened at $92.70 on Monday. The stock has a market capitalization of $12.62 billion, a PE ratio of 138.36, a PEG ratio of 1.78 and a beta of 1.19. The business’s 50 day simple moving average is $86.01 and its 200 day simple moving average is $77.57. Globus Medical, Inc. has a one year low of $49.33 and a one year high of $94.93.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.18. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The company had revenue of $625.71 million for the quarter, compared to analyst estimates of $604.69 million. During the same period in the prior year, the firm posted $0.57 EPS. The company’s quarterly revenue was up 63.1% on a year-over-year basis. As a group, research analysts expect that Globus Medical, Inc. will post 2.98 earnings per share for the current year.

Insider Transactions at Globus Medical

In other Globus Medical news, CFO Keith W. Pfeil sold 14,167 shares of Globus Medical stock in a transaction on Friday, January 10th. The shares were sold at an average price of $88.29, for a total value of $1,250,804.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Kelly Huller sold 5,000 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $81.01, for a total transaction of $405,050.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,667 shares of company stock valued at $6,674,554. Corporate insiders own 18.54% of the company’s stock.

Globus Medical Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.